Abstract
Melatonin is produced in the pineal gland as well as many other organs, including the enterochromaffin cells of the digestive mucosa. Melatonin is a powerful antioxidant that resists oxidative stress due to its capacity to directly scavenge reactive species, to modulate the antioxidant defense system by increasing the activities of antioxidant enzymes, and to stimulate the innate immune response through its direct and indirect actions. In addition, the dysregulation of the circadian system is observed to be related with alterations in colonic motility and cell disruptions due to the modifications of clock genes expression. In the gastrointestinal tract, the activities of melatonin are mediated by melatonin receptors (MT2), serotonin (5-HT), and cholecystokinin B (CCK2) receptors and via receptor-independent processes. The levels of melatonin in the gastrointestinal tract exceed by 10–100 times the blood concentrations. Also, there is an estimated 400 times more melatonin in the gut than in the pineal gland. Gut melatonin secretion is suggested to be influenced by the food intake. Low dose melatonin treatment accelerates intestinal transit time whereas high doses may decrease gut motility. Melatonin has been studied as a co-adjuvant treatment in several gastrointestinal diseases including irritable bowel syndrome (IBS), constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), Crohn's disease, ulcerative colitis, and necrotizing enterocolitis. The purpose of this review is to provide information regarding the potential benefits of melatonin as a co-adjuvant treatment in gastrointestinal diseases, especially IBS, Crohn's disease, ulcerative colitis, and necrotizing enterocolitis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 72-81 |
| Number of pages | 10 |
| Journal | Life Sciences |
| Volume | 170 |
| DOIs | |
| State | Published - Feb 1 2017 |
Fingerprint
Keywords
- Crohn's disease
- Gastrointestinal diseases
- Irritable bowel syndrome
- Melatonin
- Necrotizing enterocolitis
- Ulcerative colitis
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Melatonin's role as a co-adjuvant treatment in colonic diseases : A review. / Esteban-Zubero, Eduardo; López-Pingarrón, Laura; Alatorre-Jiménez, Moisés Alejandro; Ochoa-Moneo, Purificación; Buisac-Ramón, Celia; Rivas-Jiménez, Miguel; Castán-Ruiz, Silvia; Antoñanzas-Lombarte, Ángel; Tan, Dun Xian; García, José Joaquín; Reiter, Russel J.
In: Life Sciences, Vol. 170, 01.02.2017, p. 72-81.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Melatonin's role as a co-adjuvant treatment in colonic diseases
T2 - A review
AU - Esteban-Zubero, Eduardo
AU - López-Pingarrón, Laura
AU - Alatorre-Jiménez, Moisés Alejandro
AU - Ochoa-Moneo, Purificación
AU - Buisac-Ramón, Celia
AU - Rivas-Jiménez, Miguel
AU - Castán-Ruiz, Silvia
AU - Antoñanzas-Lombarte, Ángel
AU - Tan, Dun Xian
AU - García, José Joaquín
AU - Reiter, Russel J
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Melatonin is produced in the pineal gland as well as many other organs, including the enterochromaffin cells of the digestive mucosa. Melatonin is a powerful antioxidant that resists oxidative stress due to its capacity to directly scavenge reactive species, to modulate the antioxidant defense system by increasing the activities of antioxidant enzymes, and to stimulate the innate immune response through its direct and indirect actions. In addition, the dysregulation of the circadian system is observed to be related with alterations in colonic motility and cell disruptions due to the modifications of clock genes expression. In the gastrointestinal tract, the activities of melatonin are mediated by melatonin receptors (MT2), serotonin (5-HT), and cholecystokinin B (CCK2) receptors and via receptor-independent processes. The levels of melatonin in the gastrointestinal tract exceed by 10–100 times the blood concentrations. Also, there is an estimated 400 times more melatonin in the gut than in the pineal gland. Gut melatonin secretion is suggested to be influenced by the food intake. Low dose melatonin treatment accelerates intestinal transit time whereas high doses may decrease gut motility. Melatonin has been studied as a co-adjuvant treatment in several gastrointestinal diseases including irritable bowel syndrome (IBS), constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), Crohn's disease, ulcerative colitis, and necrotizing enterocolitis. The purpose of this review is to provide information regarding the potential benefits of melatonin as a co-adjuvant treatment in gastrointestinal diseases, especially IBS, Crohn's disease, ulcerative colitis, and necrotizing enterocolitis.
AB - Melatonin is produced in the pineal gland as well as many other organs, including the enterochromaffin cells of the digestive mucosa. Melatonin is a powerful antioxidant that resists oxidative stress due to its capacity to directly scavenge reactive species, to modulate the antioxidant defense system by increasing the activities of antioxidant enzymes, and to stimulate the innate immune response through its direct and indirect actions. In addition, the dysregulation of the circadian system is observed to be related with alterations in colonic motility and cell disruptions due to the modifications of clock genes expression. In the gastrointestinal tract, the activities of melatonin are mediated by melatonin receptors (MT2), serotonin (5-HT), and cholecystokinin B (CCK2) receptors and via receptor-independent processes. The levels of melatonin in the gastrointestinal tract exceed by 10–100 times the blood concentrations. Also, there is an estimated 400 times more melatonin in the gut than in the pineal gland. Gut melatonin secretion is suggested to be influenced by the food intake. Low dose melatonin treatment accelerates intestinal transit time whereas high doses may decrease gut motility. Melatonin has been studied as a co-adjuvant treatment in several gastrointestinal diseases including irritable bowel syndrome (IBS), constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), Crohn's disease, ulcerative colitis, and necrotizing enterocolitis. The purpose of this review is to provide information regarding the potential benefits of melatonin as a co-adjuvant treatment in gastrointestinal diseases, especially IBS, Crohn's disease, ulcerative colitis, and necrotizing enterocolitis.
KW - Crohn's disease
KW - Gastrointestinal diseases
KW - Irritable bowel syndrome
KW - Melatonin
KW - Necrotizing enterocolitis
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85008957112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85008957112&partnerID=8YFLogxK
U2 - 10.1016/j.lfs.2016.11.031
DO - 10.1016/j.lfs.2016.11.031
M3 - Review article
VL - 170
SP - 72
EP - 81
JO - Life Sciences
JF - Life Sciences
SN - 0024-3205
ER -